Exchange: NYSE·Updated 04:48 PM EDT
News
all
press releases
Should You Add Illumina Stock to Your Portfolio Now?
ILMN's sequencing growth, oncology momentum and multiomics expansion support its outlook, though cost volatility may pressure margins.
Zacks
More News
Should You Add Teleflex Stock to Your Portfolio Now?
TFX's Vascular growth, Interventional expansion and improved leverage support its outlook, while currency volatility remains a key risk.
Zacks
Is This the Right Time to Hold Medtronic Stock in Your Portfolio?
MDT's Cardiovascular gains and renal denervation growth offer upside, but tariffs and currency headwinds cloud its outlook.
Zacks
TFX or PEN: Which Is the Better Value Stock Right Now?
TFX vs. PEN: Which Stock Is the Better Value Option?
Zacks
Is it Worth Adding Veracyte Stock to Your Portfolio Now?
VCYT's Afirma and Decipher sales momentum supports growth, while competition, macro pressures and rising investments remain key concerns.
Zacks
Is TFX a Buy Now as Valuation Improves but Execution Risks Remain?
Valuation is improving for Teleflex, but slower Vascular Intervention integration and margin pressure keep execution risks in focus.
Zacks
Should You Continue to Hold Labcorp Stock in Your Portfolio?
LH's specialty-testing expansion, strategic partnerships and buybacks support growth, while reimbursement and cost pressures pose risks.
Zacks
Can Teleflex's OEM Sale and Higher EPS Outlook Reshape 2026 Returns?
TFX's $1.5B OEM sale cuts leverage and lifts 2026 EPS guidance, but weaker growth and margin pressure keep the outlook measured.
Zacks
Is it the Right Time to Retain DGX Stock in Your Portfolio?
Quest Diagnostics' growth across key channels and advanced diagnostics supports its outlook, but debt and reimbursement risks remain.
Zacks
Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now?
IDXX's CAG diagnostics and cloud software growth support recurring revenues, while FX exposure and distributor inventory swings remain key risks.
Zacks

Advertisement|Remove ads.